+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Idiopathic Pulmonary Fibrosis (Respiratory) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 697 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438137
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide 'Idiopathic Pulmonary Fibrosis - Drugs In Development, 2021', provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights


This report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 17, 45, 8, 123, 34 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionIdiopathic Pulmonary Fibrosis - OverviewIdiopathic Pulmonary Fibrosis - Therapeutics DevelopmentIdiopathic Pulmonary Fibrosis - Therapeutics AssessmentIdiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics DevelopmentIdiopathic Pulmonary Fibrosis - Drug ProfilesIdiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestonesh

Appendix
List of Tables
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AbbVie Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aeon Respire Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aluda Pharmaceuticals Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AmMax Bio Inc, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amniotics AB, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amplia Therapeutics Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp, 2021
  • Idiopathic Pulmonary Fibrosis - Pipeline by Annji Pharmaceutical Co Ltd, 2021
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, 2021
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Abeome Corp
  • Accendatech Co Ltd
  • Accro BioScience (Suzhou) Co Ltd
  • AdAlta Ltd
  • Aeon Respire Inc
  • Afimmune Biopharma Ltd
  • Algernon Pharmaceuticals Inc
  • Altavant Sciences Inc
  • Altay Therapeutics Inc
  • Aluda Pharmaceuticals Inc
  • AmMax Bio Inc
  • Amniotics AB
  • Amplia Therapeutics Ltd
  • AnaMar AB
  • Angion Biomedica Corp
  • Annji Pharmaceutical Co Ltd
  • Apaxen
  • APIE Therapeutics Inc
  • Aqua Therapeutics Co Ltd
  • Aqualung Therapeutics Corp
  • Lung Therapeutics Inc
  • Max Biopharma Inc
  • MDI Therapeutics Inc
  • Medibiofarma SL
  • Medicenna Therapeutics Corp
  • Metagone Biotech Inc
  • Metera Pharmaceuticals Inc
  • METiS Pharmaceuticals
  • Mission Therapeutics Ltd
  • MitoImmune Therapeutics Inc
  • Moerae Matrix Inc
  • Shanghai Ark Biopharmaceutical Co Ltd
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Shijiazhuang Sagacity New Drug Development Co Ltd
  • Shionogi & Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Silurian Pharmaceuticals Inc
  • Surrozen Inc
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Syndax Pharmaceuticals Inc
  • SynDevRx Inc
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Telomere Therapeutics
  • Tetragenetics Inc
  • Theravance Biopharma Inc
  • Thirona Bio Inc
  • TiumBio Co Ltd
  • TRACON Pharmaceuticals Inc
  • Translate Bio Inc
  • United Therapeutics Corp
  • Unity Biotechnology Inc
  • Vectus Biosystems Ltd
  • Velvio GmbH
  • Vicore Pharma AB
  • Viridian Therapeutics Inc
  • Wuhan LL Science and Technology Development Co Ltd
  • X-Rx Inc
  • Xfibra Inc
  • Yungjin Pharm Co Ltd